



# BSA COVID RESPONSE

## Health working group newsletter


ISSUE #3 | 17-24 April 2020

### Update on Medicines supply gaps

In last week's newsletter we reported 41 medicines identified to have availability gaps. Over the course of the week, 29 of those gaps were addressed. However, following an update to the demand models against supply, 38 additional gaps were identified. The new gaps

are detailed in our latest data request. We value your ongoing participation in this effort, especially around indicating potential ramp-up capacity (manufacture or import) for identified supply gaps. Thank you for your continued engagement.

**29** medicines gaps have been addressed




### PPE updates

1.1 million N95 masks



6 million surgical masks



8.5 million patient masks



200 ventilators



139 vetted and approved local suppliers



To register as a PPE supplier, visit <https://covid19manager.co.za/>

R400 million worth of orders placed and R360 million more in the pipeline on PPE and equipment, made possible with the help from the Solidarity Fund, Motsepe Foundation, Naspers and First Rand SPIRE fund




# Update on medicines gaps

In the updated dashboard, there are 59 SKUs (39 molecules) identified as having gaps in the public sector.

Of the identified gaps, we received confirmation from 4 manufacturers who are able to ramp up supply to meet demand on 12 of the medicines. The information has been shared with the NDoH, who will contact the respective suppliers.

We have also identified up to 16 medicines potentially at risk in the private sector. We are however still digesting data from the latest data request to quantify the gaps.



# Updated data request template

In this week's data request, you will notice an updated format. Most importantly, we have added a tab for medicine gaps. We would value input on your ability to ramp up supply to meet the identified gaps.

For any questions on the new data request, please email Sandri on:

[Sandri.Yssel@iqvia.com](mailto:Sandri.Yssel@iqvia.com)

Drug	Company	Supplier	Can you assist meeting this potential gap with additional suppliers on those indicated in the previous tabs, with the local production or importation (Y/N)	Can you assist meeting this potential gap with additional suppliers on those indicated in the previous tabs, with the local production or importation (Y/N)	Can you assist meeting this potential gap with additional suppliers on those indicated in the previous tabs, with the local production or importation (Y/N)	Can you assist meeting this potential gap with additional suppliers on those indicated in the previous tabs, with the local production or importation (Y/N)
8881614	7281222	Pharmax, South Africa	443			
8881742	7471202	Sanofi, South Africa	1 801 702			
8881743	7252020	Sanofi, South Africa	821 584			
8881744	7471202	Sanofi, South Africa	288 373			
8881745	7471202	Sanofi, South Africa	1 384			
8881746	7471202	Sanofi, South Africa	74 885			
8881747	7471202	Sanofi, South Africa	1 287			
8881748	7471202	Sanofi, South Africa	91 84			
8881749	7471202	Sanofi, South Africa	7 287			
8881750	7471202	Sanofi, South Africa	434 442			
8881751	7471202	Sanofi, South Africa	101 82			
8881752	7471202	Sanofi, South Africa	101 82			
8881753	7471202	Sanofi, South Africa	307 027			
8881754	7471202	Sanofi, South Africa	80 023			
8881755	7471202	Sanofi, South Africa	31 362			
8881756	7471202	Sanofi, South Africa	81 2			
8881757	7471202	Sanofi, South Africa	27 814			
8881758	7471202	Sanofi, South Africa	82 584			
8881759	7471202	Sanofi, South Africa	101 82			
8881760	7471202	Sanofi, South Africa	101 82			
8881761	7471202	Sanofi, South Africa	101 82			
8881762	7471202	Sanofi, South Africa	101 82			
8881763	7471202	Sanofi, South Africa	101 82			
8881764	7471202	Sanofi, South Africa	101 82			
8881765	7471202	Sanofi, South Africa	101 82			
8881766	7471202	Sanofi, South Africa	101 82			
8881767	7471202	Sanofi, South Africa	101 82			
8881768	7471202	Sanofi, South Africa	101 82			
8881769	7471202	Sanofi, South Africa	101 82			
8881770	7471202	Sanofi, South Africa	101 82			
8881771	7471202	Sanofi, South Africa	101 82			
8881772	7471202	Sanofi, South Africa	101 82			
8881773	7471202	Sanofi, South Africa	101 82			
8881774	7471202	Sanofi, South Africa	101 82			
8881775	7471202	Sanofi, South Africa	101 82			
8881776	7471202	Sanofi, South Africa	101 82			
8881777	7471202	Sanofi, South Africa	101 82			
8881778	7471202	Sanofi, South Africa	101 82			
8881779	7471202	Sanofi, South Africa	101 82			
8881780	7471202	Sanofi, South Africa	101 82			
8881781	7471202	Sanofi, South Africa	101 82			
8881782	7471202	Sanofi, South Africa	101 82			
8881783	7471202	Sanofi, South Africa	101 82			
8881784	7471202	Sanofi, South Africa	101 82			
8881785	7471202	Sanofi, South Africa	101 82			
8881786	7471202	Sanofi, South Africa	101 82			
8881787	7471202	Sanofi, South Africa	101 82			
8881788	7471202	Sanofi, South Africa	101 82			
8881789	7471202	Sanofi, South Africa	101 82			
8881790	7471202	Sanofi, South Africa	101 82			
8881791	7471202	Sanofi, South Africa	101 82			
8881792	7471202	Sanofi, South Africa	101 82			
8881793	7471202	Sanofi, South Africa	101 82			
8881794	7471202	Sanofi, South Africa	101 82			
8881795	7471202	Sanofi, South Africa	101 82			
8881796	7471202	Sanofi, South Africa	101 82			
8881797	7471202	Sanofi, South Africa	101 82			
8881798	7471202	Sanofi, South Africa	101 82			
8881799	7471202	Sanofi, South Africa	101 82			
8881800	7471202	Sanofi, South Africa	101 82			

## Medicines dashboard

We have updated our dashboard with the recent data received as of Wednesday the 15<sup>th</sup> of April.

The dashboard can be accessed from Tableau viewer. We will be in a position to share a link from next week upon request.

We expect to bring the dashboard online in the next 2 weeks.



## Section 21 applications

SAHPRA is reporting an increased interest in recent weeks around Section 21s from the industry in response to the priority list of medicines released last week.

We've been advised that Section 21 will be considered only as a last-resort after all other registered processes have been explored.

This implies first exploring potential to increase local manufacturing capacity or increasing registered imports.

We are raising this to ensure SAHPRA's capacity is allocated to the most pressing priorities at this time.

We are working with SAHPRA to put together detailed guidance around Section 21s and other regulatory processes, which we will share in the coming weeks.

## Export permits for essential medicines for SADC

We have received requests from some local manufacturers regarding delays in the processing of export permits for essential medicines destined for neighbouring countries. We raised this with the NDoH, SAHPRA, DTI and ITAC in our regular Nerve Centre meetings.

Quick feedback from the discussion:

- The NDoH has requested that **please use the INN name on the forms rather than brand names**. This would help expedite the NDoH review process.

- We've also been informed that there may be additional scrutiny on essential drugs that are already in short supply in South Africa, but this will be communicated back.

To help follow up on your applications, please send us the following information **by 8am on Monday the 20<sup>th</sup> of April 2020**:

- Company name
- Contact person and contact details
- Destination country/countries, *and*
- Date the permit was submitted.

Please email details to Sandri Yssel on:  
[Sandri.Yssel@iqvia.com](mailto:Sandri.Yssel@iqvia.com)